Orphazyme to prepare for filing of arimoclomol in Europe for Niemann-Pick disease Type C (NPC)
Jul 7, 2019
Orphazyme A/S (ticker: ORPHA.CO), a biopharmaceutical company dedicated to developing treatments for patients living with rare diseases, today announces that it has received constructive advice from the European Medicines Agency (EMA)’s Scientific Advice Working Group in response to the request for advice submitted to the agency. After receiving this feedback, Orphazyme confirms its intention to file the MAA for NPC in the first half of 2020.
Orphazyme to prepare for filing of arimoclomol in EU
Read moreMajor shareholder announcement
May 31, 2019
Orphazyme A/S (ticker: ORPHA.CO), a biopharmaceutical company dedicated to developing treatments for patients living with rare diseases, hereby announces the receipt of notification pursuant to Section 38 of the Danish Capital Markets Act from Danske Bank A/S that Danske Bank as of May 29, 2019 holds a total 998,072 shares in the Company, corresponding to 4.99% of the share capital and that Danske Bank as of May 29, 2019 controls 7.74% of the voting rights in the Company.
Major shareholder announcement
Read moreOrphazyme’s Phase II/III trial in sporadic Inclusion Body Myositis fully enrolled
Apr 23, 2019
Orphazyme A/S (ticker: ORPHA.CO), a biopharmaceutical company dedicated to developing treatments for patients living with rare diseases, today announced that its Phase II/III trial of arimoclomol for the treatment of sporadic Inclusion Body Myositis (sIBM) is fully enrolled. Performance of interim analysis and study completion expected in H1 2020 and by end 2020, respectively. Results are expected in H1 2021.
Orphazymes phase II & III trial in sporadic inclusion
Read moreMajor shareholder announcement
Apr 17, 2019
Orphazyme A/S (ticker: ORPHA.CO), a biopharmaceutical company dedicated to developing treatments for patients living with rare diseases, hereby announces the receipt of notification pursuant to Section 38 of the Danish Capital Markets Act from Danske Bank A/S that Danske Bank as of April 16, 2019 holds a total 1,000,395 shares in the Company, corresponding to 5.00% of the share capital and 7.69% of the voting rights in the Company.
Major shareholder announcement
Read moreShare capital and voting rights in Orphazyme A/S
Mar 29, 2019
Following a share capital increase in Orphazyme A/S (ticker: ORPHA.CO), CVR no. 32266355 (“Orphazyme”) in March 2019, the total nominal share capital of Orphazyme is DKK 19,984,799, divided into 19,984,799 shares each with a nominal value of DKK 1. Each share carries one vote at Orphazyme’s general meetings and accordingly the total number of voting rights in Orphazyme is 19,984,799.
Share capital and voting rights in Orphazyme as
Read moreResolution passed at the Annual General Meeting
Mar 27, 2019
Orphazyme A/S (ticker: ORPHA.CO), a biopharmaceutical company dedicated to developing treatments for patients living with rare diseases, today held its Annual General Meeting, at which the Annual General Meeting.
Resolutions passed at the annual general meeting
Read moreOrphazyme to present at Cowen & Co Annual Health Care Conference
Mar 11, 2019
Orphazyme A/S (ticker: ORPHA.CO), a biopharmaceutical company dedicated to developing treatments for patients living with rare diseases, today announced that Anders Hinsby, Chief Executive Officer at Orphazyme, will be presenting at the Cowen & Co Annual Health Care Conference in Boston, MA, USA on March 12, 2019.
Orphazyme to present at cowen co annual health care
Read moreReporting of transactions in Orphazyme’s shares made by persons discharging managerial responsibilities
Mar 8, 2019
Pursuant to the Market Abuse Regulation article 19, Orphazyme A/S, CVR no. 32266355 (“Orphazyme”), hereby notifies receipt of information of the following transactions in Orphazyme’s shares by persons discharging managerial responsibilities in Orphazyme.
Reporting of transactions in Orphazymes shares
Read moreReporting of transactions in Orphazyme’s shares made by persons discharging managerial responsibilities
Mar 7, 2019
Pursuant to the Market Abuse Regulation article 19, Orphazyme A/S, CVR no. 32266355 (“Orphazyme”), hereby notifies receipt of information of the following transactions in Orphazyme’s shares by persons discharging managerial responsibilities in Orphazyme.
Reporting of transactions in Orphazymes shares
Read moreReporting of transactions in Orphazyme’s shares made by persons discharging managerial responsibilities
Mar 5, 2019
Pursuant to the Market Abuse Regulation article 19, Orphazyme A/S, CVR no. 32266355 (“Orphazyme”), hereby notifies receipt of information of the following transactions in Orphazyme’s shares by closely associated persons to persons discharging managerial responsibilities in Orphazyme.
Reporting of transactions in Orphazymes shares
Read more